Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-1 antitrypsin - Omni Bio Pharmaceutical

Next Previous
Drug Profile

Alpha-1 antitrypsin - Omni Bio Pharmaceutical

Alternative Names: p-AAT; Plasma-derived alpha 1 antitrypsin - Omni Bio Pharmaceutical

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Colorado at Denver
  • Developer Colorado State University; Omni Bio Pharmaceutical; University of Colorado at Denver; Virginia Commonwealth University
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Enzymes; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Pancreatic elastase inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Anthrax; Graft-versus-host disease; HIV infections; Influenza virus infections; Myocardial infarction; Pneumonia; Tuberculosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 09 Dec 2014 Interim efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Graft-versus-host disease presented at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH-2014)
  • 30 Apr 2014 Final efficacy, adverse events and pharmacodynamics data from a clinical trial in Type 1 diabetes mellitus released by Omni Bio Pharmaceutical
  • 01 Dec 2013 Phase-I/II clinical trials in Myocardial infarction in USA (IV) (NCT01936896)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top